Prevention and treatment of macular degeneration and eye posterior pole
DOI:
https://doi.org/10.31288/oftalmolzh201324850Keywords:
macular degeneration and posterior pole, Ocuvite CompleteAbstract
The use of the drug Ocuvite Complete 1 capsule two times for four months helped to stabilize visual function in 83 % of patients and improve visual acuity in 26.3 % of ofpatients. Ocuvite complete serves to prevent the development of degeneration macula and posterior poles and contributes to the stabilization of visual function.
References
1.Кански Дж. Дж. Заболевания глазного дна / Дж.Дж. Кански // Под ред. С. Э. Аветисова. - М., 2008. - 3153 с.
2.Морозов В. И. Фармакотерапия глазных болезней / В. И. Морозов, А. А. Яковлев // М.: Медицина. - 2004. - 512 с.
3.Brown D. M. Ranibizumab versus verteporfm for neovas-cular age-related macular degeneration / D. M. Brown, P. K. Kaiser, М. Michels // N. Engl. J. Med. - 2006. - Vol. 5. - P. 1432- 1444 https://doi.org/10.1056/NEJMoa062655
4.Carneiro A. M. Arterial Thromboembolic Events in Patients with Exudative Age-Related Macular Degeneration Treated with Intravitreal Bevacizumab or Ranibizumab/А. М. Carneiro // Ophthalmologica. - 2011. - Feb.18. - P.211-225 https://doi.org/10.1159/000323943
5.Gaudreault J. Preclinical pharmacokinetics of Ranibizumab (rhuRabV2) after a single intravitrical administration/ J. Gaudreault, D. Fei, J. Rusit // Invest. Ophthalmol. - 2005. - Vol. - 46. - P. 726- 733. https://doi.org/10.1167/iovs.04-0601
6.Regillo C. D. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1/ C. D. Regillo, D. M. Brown, P. Abraham // Am. J. Ophthalmol. - 2008. - Vol. 145. - P. 239- 248. https://doi.org/10.1016/j.ajo.2007.10.004
7.Towler H. Age related macular degeneration // H. Towler, S. Lightman / British Medical Journal Ophthalmology. - 1996. - V.312. - P.89- 92. https://doi.org/10.1136/bmj.312.7035.889
Downloads
Published
Issue
Section
License
Copyright (c) 2013 Н. В. Коновалова, Н. И. Нарицына, А. Я. Новик, А. В. Рыбалко
This work is licensed under a Creative Commons Attribution 4.0 International License.
This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) that allows users to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author as long as they cite the source.
COPYRIGHT NOTICE
Authors who publish in this journal agree to the following terms:
- Authors hold copyright immediately after publication of their works and retain publishing rights without any restrictions.
- The copyright commencement date complies the publication date of the issue, where the article is included in.
DEPOSIT POLICY
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) during the editorial process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work with an acknowledgement of its initial publication in this journal.
- Post-print (post-refereeing manuscript version) and publisher's PDF-version self-archiving is allowed.
- Archiving the pre-print (pre-refereeing manuscript version) not allowed.
